Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 7.750-8.250 for the period, compared to the consensus earnings per share estimate of 7.860. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.7 billion. Halozyme Therapeutics also updated its FY 2025 guidance to EPS.

Halozyme Therapeutics Trading Down 2.2%

Shares of HALO stock opened at $71.71 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The company has a market cap of $8.43 billion, a PE ratio of 15.10, a P/E/G ratio of 0.32 and a beta of 0.94. The stock’s fifty day moving average price is $68.93 and its two-hundred day moving average price is $68.36.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue was up 22.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.27 EPS. Equities analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Finally, Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $78.80.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at $48,844,913.48. This trade represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 41,398 shares of company stock valued at $2,861,352. 2.40% of the stock is currently owned by corporate insiders.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the last quarter. Wexford Capital LP bought a new stake in Halozyme Therapeutics in the third quarter worth about $70,000. Employees Retirement System of Texas boosted its stake in Halozyme Therapeutics by 64.6% in the third quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 427 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Halozyme Therapeutics by 12.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 329 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.